Spotlight On RDCs, AOCs As Leading Novel Bioconjugates

 
• By Xu Hu

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

XDC concept
Bioconjugates continue to diversify • Source: Shutterstock
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from China

More from Focus On Asia